{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T23:10:20Z","timestamp":1775689820269,"version":"3.50.1"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.semarthrit.2022.152139","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T11:49:49Z","timestamp":1668685789000},"page":"152139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Systematic review on the use of biologics in adult-onset still's disease"],"prefix":"10.1016","volume":"58","author":[{"given":"Bruno","family":"Fautrel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacoby","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2453-9866","authenticated-orcid":false,"given":"Catherine","family":"Bowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mick","family":"Arber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Glanville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Mealing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviam","family":"Canon-Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Fagerhed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilde","family":"Rabijns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Giacomelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.semarthrit.2022.152139_bib0001","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1080\/1744666X.2017.1375853","article-title":"Biologic drugs in adult onset Still's disease: a systematic review and meta-analysis of observational studies","volume":"13","author":"Ruscitti","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152139_bib0002","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3109\/07853890.2014.971052","article-title":"Adult-onset Still's disease-pathogenesis, clinical manifestations, and new treatment options","volume":"47","author":"Kadavath","year":"2015","journal-title":"Ann Med"},{"key":"10.1016\/j.semarthrit.2022.152139_bib0003","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clim.2016.05.010","article-title":"Cytokine profile in adult-onset Still's disease: comparison with systemic juvenile idiopathic arthritis","volume":"169","author":"Inoue","year":"2016","journal-title":"Clin Immunol"},{"issue":"1\u20132","key":"10.1016\/j.semarthrit.2022.152139_bib0004","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s12026-014-8561-9","article-title":"Pathogenesis of adult-onset Still's disease: new insights from the juvenile counterpart","volume":"61","author":"Jamilloux","year":"2015","journal-title":"Immunol Res"},{"key":"10.1016\/j.semarthrit.2022.152139_bib0005","first-page":"50","article-title":"Gene-expression analysis of adult-onset Still's disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity","volume":"13","author":"Nirmala","year":"2015","journal-title":"Pediatr"},{"issue":"Suppl 2","key":"10.1016\/j.semarthrit.2022.152139_bib0006","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/annrheumdis-2019-eular.4535","article-title":"Management of adult-onset still's disease (AOSD) with IL-1 inhibitors: evidence-and consensus-based statements by a panel of Italian experts","volume":"78","author":"Colafrancesco","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.semarthrit.2022.152139_bib0007","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1136\/annrheumdis-2020-217155","article-title":"Canakinumab for treatment of adult-onset Still's disease to achieve reduction of arthritic manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial","volume":"79","author":"Kedor","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152139_bib0008","unstructured":"European Medicines Agency. Ilaris - EPAR: assessment report. Amsterdam: European Medicines Agency; 2016. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/ilaris-h-c-1109-ii-0043-epar-assessment-report-variation_en.pdf."},{"key":"10.1016\/j.semarthrit.2022.152139_bib0009","series-title":"Anakinra 100mg\/0.67mL solution for injection in prefilled syringe (Kineret)","year":"2018"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152139_bib0010","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13075-019-1838-6","article-title":"Adult-onset Still's disease biological treatment strategy may depend on the phenotypic dichotomy","volume":"21","author":"Vercruysse","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152139_bib0011","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1136\/ard.30.2.121","article-title":"Still's disease in the adult","volume":"30","author":"Bywaters","year":"1971","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.152139_bib0012","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.autrev.2014.08.032","article-title":"Adult onset Still's disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions","volume":"13","author":"Maria","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"10","key":"10.1016\/j.semarthrit.2022.152139_bib0013","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41584-018-0081-x","article-title":"Mechanisms, biomarkers and targets for adult-onset Still's disease","volume":"14","author":"Feist","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152139_bib0014","series-title":"Adult-onset still's disease","year":"2021"},{"key":"10.1016\/j.semarthrit.2022.152139_bib0015","article-title":"The clinical heterogeneity of adult onset Still's disease may underlie different pathogenic mechanisms. Implications for a personalised therapeutic management of these patients","author":"Ruscitti","year":"2022","journal-title":"Semin Immunol"},{"issue":"12","key":"10.1016\/j.semarthrit.2022.152139_bib0016","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10122633","article-title":"Clinical Phenotypes of Adult-Onset Still's Disease: new Insights from Pathophysiology and Literature Findings","volume":"10","author":"Mitrovic","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.semarthrit.2022.152139_bib0017","article-title":"JAK inhibitors in difficult-to-treat adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis","author":"Gillard","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152139_bib0018","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/annrheumdis-2017-212608","article-title":"Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease","volume":"77","author":"Gabay","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152139_bib0019","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2169\/internalmedicine.51.6678","article-title":"Interleukin-18 in adult-onset Still's disease: treatment target or disease activity indicator?","volume":"51","author":"Nagashima","year":"2012","journal-title":"Internal Medicine"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152139_bib0020","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s10067-005-0138-5","article-title":"A multicenter study of patients with adult-onset Still's disease compared with systemic juvenile idiopathic arthritis","volume":"25","author":"Pay","year":"2006","journal-title":"Clin Rheumatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2022.152139_bib0021","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1002\/art.27532","article-title":"Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still's disease","volume":"62","author":"Franchini","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2022.152139_bib0022","first-page":"33","article-title":"Treatment of adult-onset Still's disease: a review","volume":"11","author":"Jamilloux","year":"2015","journal-title":"Ther Clin Risk Manag"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152139_bib0023","first-page":"668","article-title":"Efficacy and safety of canakinumab in patients with Still's disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups","volume":"36","author":"Feist","year":"2018","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.152139_bib0024","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.autrev.2014.01.058","article-title":"Adult-onset Still's disease","volume":"13","author":"Gerfaud-Valentin","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"8","key":"10.1016\/j.semarthrit.2022.152139_bib0025","first-page":"e10098","article-title":"A Case Report on Adult-Onset Still's Disease Successfully Treated With Tocilizumab: a Brief Review on its Safety and Efficacy","volume":"12","author":"Nagalli","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.semarthrit.2022.152139_bib0026","series-title":"Corticosteroid adverse effects","author":"Yasir","year":"2022"},{"issue":"12","key":"10.1016\/j.semarthrit.2022.152139_bib0027","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1136\/annrheumdis-2018-213920","article-title":"Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial","volume":"77","author":"Kaneko","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152139_bib0028","first-page":"e1321","article-title":"Delay in the Diagnosis of Adult-Onset Still's Disease","volume":"9","author":"Pak","year":"2017","journal-title":"Cureus"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152139_bib0029","first-page":"e8510","article-title":"Adult-Onset Still's Disease: typical Presentation, Delayed Diagnosis","volume":"12","author":"Seco","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.semarthrit.2022.152139_bib0030","series-title":"Clinical commissioning policy: anakinra\/tocilizumab for the treatment of adult-onset still's disease refractory to second-line therapy (adults)","year":"2018"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152139_bib0031","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/MD.0000000000000021","article-title":"Adult-onset Still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients","volume":"93","author":"Gerfaud-Valentin","year":"2014","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152139_bib0032","first-page":"373","article-title":"Corticosteroid sparing effect of low dose methotrexate treatment in adult Still's disease","volume":"26","author":"Fautrel","year":"1999","journal-title":"J Rheumatol"},{"issue":"32","key":"10.1016\/j.semarthrit.2022.152139_bib0033","doi-asserted-by":"crossref","first-page":"e16682","DOI":"10.1097\/MD.0000000000016682","article-title":"Refractory adult-onset Still disease treated by tocilizumab combined with methotrexate: a STROBE-compliant article","volume":"98","author":"Wang","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"10.1016\/j.semarthrit.2022.152139_bib0034","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1080\/1744666X.2018.1536548","article-title":"Anakinra for the treatment of adult-onset Still's disease","volume":"14","author":"Casta\u00f1eda","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152139_bib0035","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/14712598.2019.1590334","article-title":"Tocilizumab for the treatment of adult-onset Still's disease","volume":"19","author":"Casta\u00f1eda","year":"2019","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152139_bib0036","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3109\/14397595.2014.974881","article-title":"Nationwide epidemiological survey of 169 patients with adult Still's disease in Japan","volume":"25","author":"Asanuma","year":"2015","journal-title":"Mod Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152139_bib0037","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/rheumatology\/ket250","article-title":"Biologic treatments for adult-onset Still's disease","volume":"53","author":"Al-Homood","year":"2013","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152139_bib0038","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/art.38296","article-title":"Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study","volume":"66","author":"Vastert","year":"2014","journal-title":"Arthritis rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152139_bib0039","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00296-019-04358-w","article-title":"Prescribing motivations and patients' characteristics related to the use of biologic drugs in adult-onset Still's disease: analysis of a multicentre \"real-life\" cohort","volume":"40","author":"Ruscitti","year":"2020","journal-title":"Rheumatol Int"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.152139_bib0040","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1080\/14712598.2019.1652591","article-title":"Biologics for the treatment of adult-onset still's disease","volume":"19","author":"Yoo","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.semarthrit.2022.152139_bib0041","unstructured":"EMA. Enbrel. 2021. [cited 16 February 2021]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/enbrel."},{"key":"10.1016\/j.semarthrit.2022.152139_bib0042","unstructured":"EMA. Humira. 2021. [cited 16 February 2021]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/humira."},{"key":"10.1016\/j.semarthrit.2022.152139_bib0043","series-title":"ClinicalTrials.gov [internet]","article-title":"Therapeutic Use of Tadekinig Alfa in Adult-onset Still's Disease","year":"2015"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152139_bib0044","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1136\/annrheumdis-2019-216699","article-title":"Tofacitinib in refractory adult-onset Still's disease: 14 cases from a single centre in China","volume":"79","author":"Hu","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152139_bib0045","series-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2019"},{"key":"10.1016\/j.semarthrit.2022.152139_bib0046","series-title":"Systematic reviews: CRD's guidance for undertaking reviews in health care","year":"2009"},{"key":"10.1016\/j.semarthrit.2022.152139_bib0047","series-title":"PROSPERO [online database]","year":"2011"},{"key":"10.1016\/j.semarthrit.2022.152139_bib0048","series-title":"EndNote [X9.3.3 for windows & mac]. [program]","year":"2020"},{"key":"10.1016\/j.semarthrit.2022.152139_bib0049","series-title":"Joanna Briggs institute reviewer's manual","article-title":"Chapter 7: systematic reviews of etiology and risk","author":"Moola","year":"2017"},{"key":"10.1016\/j.semarthrit.2022.152139_bib0050","series-title":"Cochrane handbook for systematic reviews of interventions [Version 5.1.0][updated March 2011]","article-title":"Chapter 8: assessing risk of bias in included studies","author":"Higgins","year":"2011"},{"issue":"10","key":"10.1016\/j.semarthrit.2022.152139_bib0051","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.3899\/jrheum.111549","article-title":"Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter study","volume":"39","author":"Nordstrom","year":"2012","journal-title":"J Rheumatol"},{"issue":"Suppl 1","key":"10.1016\/j.semarthrit.2022.152139_bib0052","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1136\/annrheumdis-2020-eular.2352","article-title":"Efficacy and safety of canakinumab in adult-onset still's disease: a single-center real-life experience","volume":"79","author":"Tomelleri","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152139_bib0053","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3109\/03009742.2014.992949","article-title":"Efficacy and safety of biological agents in adult-onset Still's disease","volume":"44","author":"Cavalli","year":"2015","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152139_bib0054","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10067-013-2381-5","article-title":"Tocilizumab for the treatment of adult-onset Still's disease: results from a case series","volume":"33","author":"Cipriani","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152139_bib0055","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3389\/fmed.2020.00042","article-title":"Comparison of early vs. delayed anakinra treatment in patients with adult onset Still's disease and effect on clinical and laboratory outcomes","volume":"7","author":"Vitale","year":"2020","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152139_bib0056","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/ard.2004.024026","article-title":"Club Rhumatismes et Inflammation. Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases","volume":"64","author":"Fautrel","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152139_bib0057","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13023-015-0228-7","article-title":"Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey","volume":"10","author":"Rossi-Semerano","year":"2015","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152139_bib0058","first-page":"47","article-title":"Adult-onset Still's disease: clinical, serological and therapeutic considerations","volume":"31","author":"Iliou","year":"2013","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152139_bib0059","first-page":"e13936","article-title":"Adult-onset still's disease and treatment results with tocilizumab","volume":"75","author":"Kir","year":"2020","journal-title":"Int J Clin Pract"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152139_bib0060","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3109\/14397595.2014.973659","article-title":"The effect of tocilizumab on preventing relapses in adult-onset Still's disease: a retrospective, single-center study","volume":"25","author":"Nishina","year":"2015","journal-title":"Mod Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152139_bib0061","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/art.38398","article-title":"Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still's disease: multicenter retrospective open-label study of thirty-four patients","volume":"66","author":"Ortiz-Sanjuan","year":"2014","journal-title":"Arthritis rheumatol"},{"issue":"39","key":"10.1016\/j.semarthrit.2022.152139_bib0062","doi-asserted-by":"crossref","first-page":"e1554","DOI":"10.1097\/MD.0000000000001554","article-title":"Efficacy of anakinra in refractory adult-onset Still's disease: multicenter study of 41 patients and literature review","volume":"94","author":"Ortiz-Sanjuan","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"6 Suppl 102","key":"10.1016\/j.semarthrit.2022.152139_bib0063","first-page":"S64","article-title":"Efficacy of tocilizumab therapy in Korean patients with adult-onset Still's disease: a multicentre retrospective study of 22 cases","volume":"34","author":"Song","year":"2016","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl 1","key":"10.1016\/j.semarthrit.2022.152139_bib0064","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1136\/annrheumdis-2020-eular.3491","article-title":"Tocilizumab discontinuation after remission achievement in patients with adult Still's disease","volume":"79","author":"Tamai","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"10.1016\/j.semarthrit.2022.152139_bib0065","first-page":"134","article-title":"Canakinumab treatment in adult-onset Still's disease: case series","volume":"17","author":"Ugurlu","year":"2019","journal-title":"Pediatr Rheumatol Online J"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152139_bib0066","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.semarthrit.2020.10.011","article-title":"Outcome of refractory to conventional and\/or biologic treatment adult Still's disease following canakinumab treatment: countrywide data in 50 patients","volume":"51","author":"Laskari","year":"2021","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152139_bib0067","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/ard.2007.076034","article-title":"Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France","volume":"67","author":"Lequerre","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152139_bib0068","series-title":"American college of rheumatology 20\/50\/70 criteria (ACR20\/50\/70)","author":"Felson","year":"1993"},{"key":"10.1016\/j.semarthrit.2022.152139_bib0069","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152089","article-title":"Efficacy and safety of tocilizumab in adult-onset Still's disease: real-life experience from the international AIDA registry","volume":"57","author":"Sota","year":"2022","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152139_bib0070","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/acr.21901","article-title":"Anakinra in adult-onset Still's disease: long-term treatment in patients resistant to conventional therapy","volume":"65","author":"Giampietro","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"10.1016\/j.semarthrit.2022.152139_bib0071","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1080\/14740338.2020.1839411","article-title":"Current treatment options and safety considerations when treating adult-onset Still's disease","volume":"19","author":"Cavalli","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.semarthrit.2022.152139_bib0072","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2147\/TCRM.S155488","article-title":"Biological therapy of traditional therapy-resistant adult-onset Still's disease: an evidence-based review","volume":"14","author":"Zhou","year":"2018","journal-title":"Ther Clin Risk Manag"},{"issue":"9","key":"10.1016\/j.semarthrit.2022.152139_bib0073","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1093\/rheumatology\/keab485","article-title":"Current and emerging biological therapy in adult-onset Still's disease","volume":"60","author":"Ma","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2022.152139_bib0074","unstructured":"EULAR. EULAR Task Force Ongoing Initiatives. 2022. Available from: https:\/\/www.eular.org\/ongoing_initiatives.cfm."},{"issue":"11","key":"10.1016\/j.semarthrit.2022.152139_bib0075","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1080\/1744666X.2017.1372194","article-title":"Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets?","volume":"13","author":"Ruscitti","year":"2017","journal-title":"Expert Rev Clin Immunol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222001901?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222001901?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:09:55Z","timestamp":1758733795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017222001901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":75,"alternative-id":["S0049017222001901"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152139","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic review on the use of biologics in adult-onset still's disease","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152139","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152139"}}